Loading
Vantis, a Munich-based healthcare technology company, has successfully secured €10 million in a new funding round. The investment was led by Angelini Ventures, with significant participation from Bayern Kapital, Twip Impact Ventures, firstminute capital, and b2venture. This capital infusion is intended to advance Vantis's work in early disease detection and expand its market presence.
Vantis focuses on developing innovative at-home diagnostic solutions, with its flagship product being a CE-marked urine test designed for the early detection of chronic kidney disease (CKD). The company plans to utilize the newly acquired funds to expand the reach of its at-
Funding Round: Unknown
Amount Raised: €10M
Valuation: Unknown
Lead Investor: Angelini Ventures
Other Funds that Invested: Bayern Kapital, Twip Impact Ventures, firstminute, b2venture
Company Industry: Hospital & Health Care
Company Headquarters: Munich, Germany
Join thousands of founders using our technology to find the right investors and close rounds faster than ever before.